Picture of Crispr Therapeutics AG logo

CRSP — Crispr Therapeutics AG News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapMomentum Trap

Swiss stocks - Factors to watch on December 11

ZURICH/BERLIN, Dec 11 (Reuters) - Here are some of the
main factors that may affect Swiss stocks on Monday:
    
    SWISS NATIONAL BANK  SNBN.S 
    Reuters will publish a poll of economists on their outlook
for the Swiss National Bank monetary policy.
    
    UBS  UBSG.S 
    UBS has been hit with $400 million of Credit Suisse-linked
property costs, reported the Financial Times. 
    Bloomberg News separately reported that UBS tapped
JPMorgan's Tommy Rueger as co-head of equity capital markets.
    
    CRISPR THERAPEUTICS  CRSP.BN 
    The U.S. Food and Drug Administration (FDA) on Friday
approved two gene therapies for sickle cell disease, making one
of them the first treatment in the United States based on the
Nobel Prize-winning CRISPR gene editing technology.
    Casgevy, developed by partners Vertex Pharmaceuticals
 VRTX.O  and CRISPR Therapeutics, and bluebird bio's  BLUE.O 
Lyfgenia were approved for people aged 12 years and older.
      
    COMPANY STATEMENTS
    *Roche  ROG.S  said a study revealed Inavolisib combination
reduces risk of breast cancer progression.  ROG.S 
    *Roche  ROG.S  also announced that Kadcyla shows overall
survival benefit in people with breast cancer.  ROG.S 
    *Helvetica  HSCF.S  announced Marc Giraudon's appointment as
co-CEO starting Jan 1, transitioning to sole CEO on July 1.
 HSCF.S 
    *Molecular Partners  MOLN.S  presented positive initial data
from the first four dosing cohorts of ongoing phase 1/2A trial
of MP0533.  MOLN.S 
    *Novartis  NOVN.S  said new 48-week results from Phase III
APPLY-PNH trial showed sustained efficacy and long-term safety
of Fabhalta.  NOVN.S 
    
    ANALYSTS' VIEWS
    CRISPR THERAPEUTICS AG  CRSP.O : TRUIST SECURITIES CUTS
TARGET PRICE TO $160 FROM $220
    
    ECONOMY
    SNB data on Swiss sight deposits due at 0900 GMT.

 (Reporting by Zurich newsroom and Berlin Speed Desk)
 ((+41 58 306 7336; zurich.newsroom@thomsonreuters.com))
 
((For Top News in a multimedia Web format on Eikon visit: https://bit.ly/2NDFd6g
FOR RELATED PRICES, NEWS AND OTHER TOPICS, DOUBLE-CLICK ON:
Daily Swiss stock market report in German  .SDE 
All SMI constituent stocks  0#.SSMI 
DJ STOXX index  .STOXX 
Top 10 STOXX sectors  .PGL.STOXXS 
Top 10 EUROSTOXX sectors  .PGL.STOXXES 
Swiss mid-cap index  .SSMI 
Swiss all-share index  .SSHI 
Swiss market digest  .AD.S 
Sector overview  CH/SECTOR1 
All Swiss news  CH 
Swiss research news  CH-RCH   
All equity news  E 
SPEED GUIDES:   EQUITY   EQUITY/NEWS1   EUR/EQUITY   SWITZERLAND   REUTERS  ))

Recent news on Crispr Therapeutics AG

See all news